Feb. 4 at 12:08 AM
$NNDM Nano Dimension Schedule 13D – Oramed / Nadav Kidron
Who filed:
• Oramed Pharmaceuticals, Inc.
• Nadav Kidron (CEO of Oramed) jointly as reporting persons.
Stake size and shares:
• 10,549,430 ordinary shares beneficially owned in Nano Dimension — representing 5.0 % of the company’s outstanding shares (based on ~210.3 million shares outstanding).
Cost of position:
• The filing states that Oramed and Kidron spent approximately ~
$18.25 million to acquire the 5 % position (excluding commissions).
Source of funds:
• Shares acquired with Oramed’s general working capital for the portion held by Oramed (10,413,730 shares).
• The remaining 135,700 shares were purchased with Mr. Kidron’s personal funds.
Purpose / Intent:
• They stated they intend to engage with Nano Dimension’s management, board and shareholders — discussing business strategy, governance, performance, and potentially recommending changes including board composition.
• The filing also notes they may buy more shares
